AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19665279
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone analogue (tryptorelin or leuprorelin, 3.75 mg every 28 days)
Trial: 19665279
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose monophasic oral contraceptives (ethynilestradiol, 0.03 mg plus gestoden, 0.75 mg)
Trial: 17052809
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition enriched with carotenoids (3-mg/1500kcal) for 3 months
Trial: 7831376
Drug: HA-1A treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1A treatment
Trial: 3078426
Drug: Nifedipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (4 mcg/Kg/L) added to cold potassium cardioplegia
Trial: 16775510
Drug: Ethanol-water solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol-water solution (ET)
Trial: 15181040
Drug: r‐metHuLeptin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐metHuLeptin 0.1 mg/kg
Trial: 15181040
Drug: r‐metHuLeptin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐metHuLeptin 0.3 mg/kg
Trial: 15181040
Drug: r‐metHuLeptin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐metHuLeptin 1.0 mg/kg
Trial: 15181040
Drug: r‐metHuLeptin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐metHuLeptin (all doses)
Trial: 11303370
Drug: Lansoprazole and
RxNorm normalized name: Lansoprazole and naproxen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole and two antibacterial agents chosen according to susceptibility test
Trial: 11303370
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy based on proton pump inhibitor and two antibiotics
Trial: 11303370
Drug: Gastric-mucosal culture
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric-mucosal culture testing for sensitivity of H. pylori to antibiotics
Trial: 8287568
Drug: hGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH treatment (group I) for 12 months
Trial: 8287568
Drug: hGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH treatment (group I)
Trial: 22724427
Drug: 0.91 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.91 ml/kg vodka
Trial: 22724427
Drug: 1.82 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.82 ml/kg energy drink
Trial: 2067362
Drug: Protamine pretreatment
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine pretreatment (PP) 2 mg/kg
Trial: 29030065
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment (40mg bolus of furosemide)
Trial: 29030065
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion (500mL of saline infusion)
Trial: 15365927
Drug: Ketorolac and
RxNorm normalized name: Ketorolac and phenylephrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac and opioid analgesics
Trial: 2453744
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 mg, twice daily for 24 hours)
Trial: 2453744
Drug: Acebutolol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (480 mg, twice daily for 3 weeks)
Trial: 2453744
Drug: Acebutolol (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (acute and long-term treatment)
Trial: 26329656
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) with low dosage of fentanyl (15 μg/kg)
Trial: 26329656
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage of fentanyl (30 μg/kg) with normal saline (control group)
Trial: 24010549
Drug: Moderate red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate red wine intake (250 mL/day for 4 weeks)
Trial: 14673053
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of oral paroxetine hydrochloride daily
Trial: 1424424
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 to 60 mg)
Trial: 6731879
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg of cimetidine only
Trial: 6731879
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg of metoclopramide only
Trial: 6731879
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg of cimetidine and 0.15 mg/kg of metoclopramide
Trial: 31087542
Drug: TCZ‐SC 162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ‐SC 162 mg qw
Trial: 18602824
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (5 g, twice daily for 4 weeks)
Trial: 16429095
Drug: Parents who
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents who responded to antidepressant therapy (defined as at least a 40% reduction in depressive symptoms)
Trial: 16429095
Drug: Parents who
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents who did not respond to antidepressant therapy
Trial: 16429095
Drug: Parents who
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents who responded to treatment
Trial: 16429095
Drug: Parents who
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents who did not respond to treatment
Trial: 1426499
Drug: Progesterone pessaries
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone pessaries 100 mg b.d. from 48 hours prior to embryo transfer and continued throughout the luteal phase
Trial: 30504510
Drug: DMARD tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMARD tapering by 50% (arm 2)
Trial: 30504510
Drug: Stopping DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping DMARD after tapering (arm 3)
Trial: 30504510
Drug: Full-dose DMARD
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose DMARD treatment
Trial: 30504510
Drug: Tapering and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering and stopping DMARD in low-risk relapse group
Trial: 27259714
Drug: Chemotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy of physician's choice plus trastuzumab (gemcitabine, capecitabine, or vinorelbine)
Trial: 22512435
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (1000 mg testosterone undecanoate intramuscular injections at 0, 6, and 12 weeks)
Trial: 15949795
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% diclofenac
Trial: 12385927
Drug: Therapeutic alpha-blockers
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic alpha-blockers
Trial: 1801386
Drug: Otovent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otovent treatment for two weeks
Trial: 7230728
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment (1.5 g/day)
Trial: 8938176
Drug: Phenprocoumon treatment
RxNorm normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenprocoumon treatment
Trial: 7230728
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups after one year
Trial: 19491796
Drug: Aqua Maris
RxNorm normalized name: Aqua Maris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua Maris nasal spray (thrice daily)
Trial: 23754628
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (Control)
Trial: 17955784
Drug: Donepezil, Galantamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil, Galantamine, Rivastigmine (acetylcholinesterase inhibitors)
Trial: 17955784
Drug: Memantine (glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (glutamate antagonist)
Trial: 17955784
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetylcholinesterase inhibitors or memantine
Trial: 10601178
Drug: DHEA (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (150 mg/day)
Trial: 10601178
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg acute ingestion)
Trial: 31686175
Drug: Nicotine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (7 mg/24 h, transdermally) and galantamine (4 mg, p.o.) combined
Trial: 31686175
Drug: Nicotine alone
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine alone (7 mg/24 h, transdermally)
Trial: 31686175
Drug: Galantamine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine alone (4 mg, p.o.)
Trial: 31686175
Drug: Galantamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (4 mg, p.o.)
Trial: 28251402
Drug: BRJ (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRJ (140 ml concentrated nitrate-rich beetroot juice, 12.5 mmol nitrate)
Trial: 26198373
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m² plus vinorelbine 60 mg/m²
Trial: 26198373
Drug: Vinorelbine doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine doses per kg LBM
Trial: 26198373
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction and/or stop of treatment
Trial: 16531896
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (10,000 IU beta-carotene, 200 IU alpha-tocopherol acetate, 250 mg ascorbic acid, 50 microg selenium, 15 mg zinc)
Trial: 15193678
Drug: Fondaparinux 4
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux 4 mg once daily
Trial: 15193678
Drug: Fondaparinux 8
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux 8 mg once daily
Trial: 15193678
Drug: Fondaparinux 12
RxNorm normalized name: fondaparinux 12.5 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 12 mg once daily
Trial: 15193678
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg once daily (per-protocol analysis)
Trial: 15193678
Drug: Fondaparinux 4
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux 4 mg once daily (per-protocol analysis)
Trial: 15193678
Drug: Fondaparinux 8
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux 8 mg once daily (per-protocol analysis)
Trial: 15193678
Drug: Fondaparinux 12
RxNorm normalized name: fondaparinux 12.5 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 12 mg once daily (per-protocol analysis)
Trial: 15193678
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg twice daily (per-protocol analysis)
Trial: 10411250
Drug: Low-dose methyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methyl prednisolone sodium succinate (MPSS) 1 mg/kg
Trial: 10411250
Drug: Low-dose methyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methyl prednisolone sodium succinate (MPSS)
Trial: 7550814
Drug: Trivalent subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent subvirion influenza virus vaccine
Trial: 6990861
Drug: Cimetidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.0 g daily) for four weeks
Trial: 30215583
Drug: Control commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control commercial vaccine
Trial: 10583317
Drug: Lysine vasopressin
RxNorm normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine vasopressin (LVP) administration with minimal dose of GH-RH (0.035 microg/kg BW)
Trial: 10583317
Drug: Lysine vasopressin
RxNorm normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine vasopressin (LVP) administration with maximal dose of GH-RH (100 microg)
Trial: 10583317
Drug: Lysine vasopressin
RxNorm normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine vasopressin (LVP) administration with arginine (30 g over 30 min)
Trial: 10583317
Drug: Lysine vasopressin
RxNorm normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine vasopressin (LVP) administration with clonidine (150 microg)
Trial: 10583317
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administration
Trial: 7589051
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem LP 300 mg
Trial: 29161998
Drug: MMT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMT plus CRT (Cognitive Rehabilitation Treatment) for two months
Trial: 26923256
Drug: Donepezil 23
RxNorm normalized name: donepezil 23 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 23 mg
Trial: 25530384
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg doxazosin XL
Trial: 25530384
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg doxazosin XL
Trial: 25530384
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg doxazosin XL (group 1b)
Trial: 25530384
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg doxazosin XL (group 1b)
Trial: 19446151
Drug: Dispersible tablet
RxNorm normalized name: Aspirin 75 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet formulation of arbidol 200 mg
Trial: 19446151
Drug: Branded capsule
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded capsule formulation of arbidol 200 mg
Trial: 17224848
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of lopinavir/ritonavir (800/200 mg or 400/100 mg)
Trial: 17224848
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of lopinavir/ritonavir
Trial: 17224848
Drug: Soft-gelatin capsule
RxNorm normalized name: ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Soft-gelatin capsule (SGC) formulation of lopinavir/ritonavir
Trial: 15042010
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (400 microg every 4 hours for 24 hours)
Trial: 15042010
Drug: Intra-amniotic PGF(2alpha)
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic PGF(2alpha) (40 mg followed by oxytocin infusion)
Trial: 8192104
Drug: Acivicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acivicin 60 mg/m2 as a continuous intravenous infusion over 72 hours, repeated every 28 days
Trial: 8192104
Drug: Etoposide 120
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 120 mg/m2 daily on days 1, 2, and 3 and cisplatin 60 mg/m2 intravenously on day 1, repeated every 28 days
Trial: 3300325
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy and No therapy
Trial: 22020244
Drug: Pre-hospital cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital cooling using a rapid infusion of up to two litres ice-cold Hartmann's solution (82 patients)
Trial: 15681958
Drug: S-Caine Patch
RxNorm normalized name: Comfort Caine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Caine Patch
Trial: 12958723
Drug: Anticoagulation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation group (Group A) - Heparin intravenously with target aPTT 50-70 seconds
Trial: 12958723
Drug: Non-anticoagulation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anticoagulation group (Group B) - No intravenous heparin
Trial: 1990794
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of intravenous verapamil
Trial: 1990794
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 10% intravenous calcium chloride followed by 10 mg of intravenous verapamil
Trial: 1990794
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.9% intravenous sodium chloride followed by 10 mg of intravenous verapamil
Trial: 1990794
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 10% intravenous calcium chloride followed by 4 ml of 0.9% intravenous sodium chloride
Trial: 6848891
Drug: Thymectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymectomy with azathioprine therapy for 1 year
Trial: 6848891
Drug: Thymectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thymectomy without azathioprine therapy for 1 year
Trial: 22196293
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone via iontophoresis
Trial: 22196293
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone injection
Trial: 22196293
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg triamcinolone injection
Trial: 20303788
Drug: Omega-3 fish
RxNorm normalized name: Omega-3 Fish Oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fish oil supplementation (2.1 g/day) for 90 days
Trial: 17673448
Drug: Dual-antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet therapy (aspirin plus clopidogrel)
Trial: 14730323
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy followed by angioplasty after 3 months (Med-PTRA)
Trial: 7893284
Drug: bezafibrate 200
RxNorm normalized name: bezafibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate 200 mg 3 times a day
Trial: 25738345
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (CAF + CTG and CAF)
Trial: 19116603
Drug: MPSV4 (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPSV4 (licensed unconjugated quadrivalent polysaccharide vaccine)
Trial: 15022127
Drug: pressurized metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurized metered dose inhaler and valved holding chamber (pMDI VHC)
Trial: 363347
Drug: Subdermal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal implants of levonorgestrel
Trial: 363347
Drug: Subdermal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal implants of norgestrel
Trial: 22046961
Drug: BUD/FORM 160/4.5 μg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FORM 160/4.5 μg, two inhalations twice daily
Trial: 22046961
Drug: BUD 200 μg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD 200 μg, two inhalations twice daily
Trial: 15347715
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 20 mg/kg every 12 hours for 48-72 hours